271 related articles for article (PubMed ID: 9736420)
21. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.
Li Y; Rodriquez M; Spencer FA; Becker RC
J Thromb Thrombolysis; 2002 Oct; 14(2):123-9. PubMed ID: 12714831
[TBL] [Abstract][Full Text] [Related]
22. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients.
Brown JR; Kuter DJ
Thromb Haemost; 2001 Jun; 85(6):979-85. PubMed ID: 11434705
[TBL] [Abstract][Full Text] [Related]
23. Methods for administering subcutaneous heparin during pregnancy.
Sasaki H; Yonemoto N; Hanada N; Mori R
Cochrane Database Syst Rev; 2013 Mar; (3):CD009136. PubMed ID: 23543570
[TBL] [Abstract][Full Text] [Related]
24. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
[TBL] [Abstract][Full Text] [Related]
25. Heparin induces mobilization of osteoprotegerin into the circulation.
Vik A; Brodin E; Sveinbjørnsson B; Hansen JB
Thromb Haemost; 2007 Jul; 98(1):148-54. PubMed ID: 17598007
[TBL] [Abstract][Full Text] [Related]
26. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE
Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751
[TBL] [Abstract][Full Text] [Related]
27. Bleeding risk during treatment of acute thrombotic events with subcutaneous LMWH compared to intravenous unfractionated heparin; a systematic review.
Costantino G; Ceriani E; Rusconi AM; Podda GM; Montano N; Duca P; Cattaneo M; Casazza G
PLoS One; 2012; 7(9):e44553. PubMed ID: 22984525
[TBL] [Abstract][Full Text] [Related]
28. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
29. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
30. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
31. Repeated doses of oral and subcutaneous heparins have similar antithrombotic effects in a rat carotid arterial model of thrombosis.
Hiebert LM; Ping T; Wice SM
J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):110-6. PubMed ID: 21512111
[TBL] [Abstract][Full Text] [Related]
32. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma.
Alban S
Semin Thromb Hemost; 2001 Oct; 27(5):503-11. PubMed ID: 11668420
[TBL] [Abstract][Full Text] [Related]
33. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
van Dongen CJ; van den Belt AG; Prins MH; Lensing AW
Cochrane Database Syst Rev; 2004 Oct; (4):CD001100. PubMed ID: 15495007
[TBL] [Abstract][Full Text] [Related]
34. A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans.
Kaiser B; Glusa E; Hoppensteadt DA; Breddin HK; Amiral J; Fareed J
Blood Coagul Fibrinolysis; 1998 Sep; 9(6):517-23. PubMed ID: 9819002
[TBL] [Abstract][Full Text] [Related]
35. Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
Hiebert LM
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):264-272. PubMed ID: 27653610
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
37. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
[TBL] [Abstract][Full Text] [Related]
38. Low-molecular-weight heparins in thrombosis and cancer: emerging links.
Mousa SA
Cardiovasc Drug Rev; 2004; 22(2):121-34. PubMed ID: 15179449
[TBL] [Abstract][Full Text] [Related]
39. Orally active heparin and low-molecular-weight heparin.
Pineo GF; Hull RD; Marder VJ
Curr Opin Pulm Med; 2001 Sep; 7(5):344-8. PubMed ID: 11584187
[TBL] [Abstract][Full Text] [Related]
40. Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins.
Bendz B; Andersen TO; Sandset PM
Blood Coagul Fibrinolysis; 2000 Jun; 11(4):343-8. PubMed ID: 10847421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
